Overview

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Status:
NOT_YET_RECRUITING

Trial end date:
2030-09-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum and pemetrexed as the first-line treatment for the locally advanced or metastatic KRASG12C mutation-positive non-squamous non-small cell lung cancer (NSCLC).

Phase:

PHASE3

Details

Lead Sponsor:

InxMed (Shanghai) Co., Ltd.

Treatments:

Pemetrexed
Platinum